DP1038

DP1038 is a novel intranasal formulation of octreotide acetate developed by Dauntless Pharmaceuticals. It is designed as a non-invasive alternative to injectable somatostatin analogs for the treatment of acromegaly and neuroendocrine tumors. Octreotide is a synthetic peptide analog of somatostatin that inhibits the secretion of growth hormone (GH) from pituitary adenomas and other hormones from neuroendocrine tumors. The mechanism involves agonism at somatostatin receptors, leading to suppression of GH and insulin-like growth factor 1 (IGF-1) levels. DP1038 leverages patented absorption technology from Aegis Therapeutics to enhance nasal bioavailability, aiming to provide efficacy comparable to subcutaneous injections with improved patient convenience and tolerability[2][3][4][5][7].

Other names

intranasal octreotideoctreotide acetate intranasal formulation